EP
PVLA

Eversept Partners’s Palvella Therapeutics PVLA Stock Holding History

Eversept Partners’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,343
Closed -$711K – 123
2025
Q3 		$711K Buy
+11,343
New +$506K 0.05% 80

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Eversept Partners's PVLA Position: Q4 2025 in Review

Eversept Partners sold out of Palvella Therapeutics (PVLA) in Q4 2025, closing a stake of 11,343 shares — an estimated $711K sold.

Eversept Partners first reported a position in PVLA in Q3 2025 and held it in 1 quarter. The position peaked at $711K in Q3 2025. 140 funds tracked by Wall St. Rank hold PVLA as of Q4 2025.

  • Eversept Partners reported no remaining Palvella Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Eversept Partners sold 11,343 Palvella Therapeutics shares in Q4 2025, an estimated $711K.
  • Eversept Partners first reported a position in Palvella Therapeutics in Q3 2025 and held it in 1 quarter.
  • Eversept Partners's Palvella Therapeutics position peaked at $711K in Q3 2025.
  • 140 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2025.

Based on Eversept Partners's 13F filing for Q4 2025, filed 17 Feb 2026.